Search

Your search keyword '"Romito, Alessia"' showing total 29 results
Start Over Author "Romito, Alessia"
29 results on '"Romito, Alessia"'

7. Techniques for sentinel node biopsy in breast cancer

Author

BOVE, Sonia, primary, FRAGOMENI, Simona M., additional, ROMITO, Alessia, additional, DI GIORGIO, Danilo, additional, RINALDI, Pierluigi, additional, PAGLIARA, Domenico, additional, VERRI, Debora, additional, ROMITO, Ilaria, additional, PARIS, Ida, additional, TAGLIAFERRI, Luca, additional, MARAZZI, Fabio, additional, VISCONTI, Giuseppe, additional, FRANCESCHINI, Gianluca, additional, MASETTI, Riccardo, additional, and GARGANESE, Giorgia, additional

Published
2021
Full Text
View/download PDF

9. Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis

Author

Romito, Alessia, primary, Bove, Sonia, additional, Romito, Ilaria, additional, Zace, Drieda, additional, Raimondo, Ivano, additional, Fragomeni, Simona Maria, additional, Rinaldi, Pierluigi Maria, additional, Pagliara, Domenico, additional, Lai, Antonella, additional, Marazzi, Fabio, additional, Marchetti, Claudia, additional, Paris, Ida, additional, Franceschini, Gianluca, additional, Masetti, Riccardo, additional, Scambia, Giovanni, additional, Fabi, Alessandra, additional, and Garganese, Giorgia, additional

Published
2021
Full Text
View/download PDF

10. Techniques for sentinel node biopsy in breast cancer

Author

Bove, Sonia, Fragomeni, Simona Maria, Romito, Alessia, DI Giorgio, Danilo, Rinaldi, Pierluigi, Pagliara, Domenico, Verri, Debora, Romito, Ilaria, Paris, Ida, Tagliaferri, Luca, Marazzi, Fabio, Visconti, Giuseppe, Franceschini, Gianluca, Masetti, Riccardo, Garganese, Giorgia, Fragomeni, Simona M, Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Visconti, Giuseppe (ORCID:0000-0002-0041-5420), Franceschini, Gianluca (ORCID:0000-0002-2950-3395), Masetti, Riccardo (ORCID:0000-0002-7520-9111), Garganese, Giorgia (ORCID:0000-0002-4209-5285), Bove, Sonia, Fragomeni, Simona Maria, Romito, Alessia, DI Giorgio, Danilo, Rinaldi, Pierluigi, Pagliara, Domenico, Verri, Debora, Romito, Ilaria, Paris, Ida, Tagliaferri, Luca, Marazzi, Fabio, Visconti, Giuseppe, Franceschini, Gianluca, Masetti, Riccardo, Garganese, Giorgia, Fragomeni, Simona M, Tagliaferri, Luca (ORCID:0000-0003-2308-0982), Visconti, Giuseppe (ORCID:0000-0002-0041-5420), Franceschini, Gianluca (ORCID:0000-0002-2950-3395), Masetti, Riccardo (ORCID:0000-0002-7520-9111), and Garganese, Giorgia (ORCID:0000-0002-4209-5285)

Abstract

Introduction: Sentinel node biopsy (SNB) is the standard of care in women with breast cancer (BC) and clinically non suspicious axillary lymph nodes (LNs), due to its high negative predictive value (NPV) in the assessment of nodal status. SNB has significantly reduced complications related to the axillary lymph node dissection, such as lymphedema and upper limb dysfunction. Evidence acquisition: The gold standard technique for SNB is the blue dye (BD) and technetium labelled nanocolloid (Tc-99m) double technique. However, nuclear medicine is not available in all Institutions and several new tracers and devices have been proposed, such as indocyanine green (ICG) and superparamagnetic iron oxides (SPIO). All these techniques show an accuracy and detection rate not inferior to that of the standard technique, with different specific pros and cons. The choice of how to perform a SNB primarily depends on the surgeon's confidence with the procedure, the availability of nuclear medicine and the economic resources of the Institutions. In this setting, new tracers, hybrid tracers and imaging techniques are being evaluated in order to improve the detection rate of sentinel lymph nodes (SNs) and minimize the number of unnecessary axillary surgeries through an accurate preoperative assessment of nodal status and to guide new minimally invasive diagnostic procedures of SNs. In particular, the contrast-enhanced ultrasound (CEUS) is an active field of research but cannot be recommended for clinical use at this time. Evidence synthesis: The ICG fluorescence technique was superior in terms of DR, as well as having the lowest FNR. The DR descending order was SPIO, Tc, dual modality (Tc/BD), CEUS and BD. Conclusions: This paper is a narrative review of the most common SNB techniques in BC with a focus on recent innovations.

Published
2021

12. Heterogeneity Among Poor Ovarian Responders According to Bologna Criteria Results in Diverging Cumulative Live Birth Rates

Author

Romito, Alessia, primary, Bardhi, Erlisa, additional, Errazuriz, Joaquin, additional, Blockeel, Christophe, additional, Santos-Ribeiro, Samuel, additional, Vos, Michel De, additional, Racca, Annalisa, additional, Mackens, Shari, additional, Kelen, Annelore Van Der, additional, Panici, Pierluigi Benedetti, additional, Vaiarelli, Alberto, additional, Tournaye, Herman, additional, and Drakopoulos, Panagiotis, additional

Published
2020
Full Text
View/download PDF

14. Cumulative live birth rates in women with poor ovarian response (POR) meeting the Bologna criteria: the importance of the phenotype

Author

Romito, Alessia, Blockeel, Christophe, Errazuriz Valenzuela, Joaquin, De Vos, Michel, Santos-Ribeiro, Samuel, Van Der Kelen, Annelore, Mackens, Shari, Racca, Annalisa, Benedetti Panici, P., Tournaye, Herman, Drakopoulos, Panagiotis, Centre for Reproductive Medicine - Gynaecology, Surgical clinical sciences, Reproduction and Genetics, Faculty of Medicine and Pharmacy, Reproductive immunology and implantation, Biology of the Testis, and Follicle Biology

Abstract

Study question: Does reproductive outcome differ among the various types of women with . poor ovarian response (POR) meeting the Bologna criteria?ummary answer: Live birth rates (LBR) and cumulative LBR differ significantly among Bologna POR patients. What is known already: In 2011, the European Society of Human Reproduction and Embryology (ESHRE) elaborated on the definition of women with inadequate response to ovarian stimulation. This consensus definition—known as the Bologna criteria was initially introduced with the primary objective of standardising the definition of POR. However, the Bologna criteria may have merged various patient cate- gories with potentially different prognosis. Evidence regarding the reproductive outcome of different categories of patients is sparse. Study design, size, duration: his was a retrospective cohort analysis carried out at a university based tertiary centre aiming to evaluate cumulative LBR in different categories of . Bologna POR. All Bologna POR patients who underwent ovarian stimulation or ART using a GnRH-antagonist protocol from 1st January 2011 until 31th December 2017 were included in the study. Participants/materials, setting, methods: Women were divided in four categories according to their Bologna criteria pattern: group A women ≥ 40 years with an abnormal ovarian reserve test; group B women ≥ 40 years with an abnormal ovarian reserve markers and one previous cycle with poor response; women in group C were ≥ 40 years and had one previous cycle with poor response; group D patients with an abnormal ovarian reserve test and one previous cycle with poor response. Main results and the role of chance: In total 846 cycles in 706 Bologna POR patients were included in the analysis: 310 cycles in group A, 169 in group B, 52 in group C and 315 in group D. There were significant differences in female age, antral follicle count, antimüllerian hor- mone, cycle cancellation rates and number of retrieved oocytes between the four groups. LBR and cumulative LBR differed significantly between groups and were highest in Group D (LBR: 7.4% (A) vs. 4.1% (B) vs. 5.8% (C) vs. 13.4% (D), p =0.001 and CLBR: 8.3% (A) vs. 4.1 % (B) vs. 9.6% (C) vs. 16.8% (D) p

Published
2019

15. First-line treatment of women with advanced ovarian cancer: focus on bevacizumab

Author

Marchetti,Claudia, Muzii,Ludovico, Romito,Alessia, and Benedetti Panici,Pierluigi

Subjects
OncoTargets and Therapy
Abstract

Claudia Marchetti, Ludovico Muzii, Alessia Romito, Pierluigi Benedetti Panici Department of Gynecological-Obstetrical and Urological Sciences, Sapienza University of Rome, Rome, Italy Abstract: Ovarian cancer is the fifth most common cause of cancer death in women in Europe. Despite the progress, almost 70% of the patients relapse. The standard treatment is cytoreductive surgery followed by platinum-taxane chemotherapy; in patients with a disseminated disease, one option is neoadjuvant chemotherapy with delayed surgery (ie, interval debulking surgery). The most important change in the last decades involved the schedule treatment and the addition of new drugs to first-line therapy. Because of the pathogenetic role of angiogenesis in solid-tumor growth and metastasis, research has been concentrated on anti-angiogenetic drug. Bevacizumab, the most promising anti-angiogenetic drug, is a humanized monoclonal IgG antibody that targets vascular endothelial growth factor receptor. It was approved on December 23, 2011 by the European Medicines Agency and on June 13, 2018 by the Food and Drug administration as first-line treatment in epithelial ovarian, fallopian tube, or primary peritoneal cancer stage III or IV in combination with carboplatin and paclitaxel. There are still some doubts, regarding the schedule, dosage, duration of the treatment, safety, and tolerability, both in first-line and in neoadjuvant chemotherapy treatments. This review tries to answer clinical practice questions and summarizes the evidence from Phase III studies, emerging data, and ongoing trials. Keywords: ovarian cancer, first-line treatment, bevacizumab, anti-angiogenesis

Published
2019

16. Pituitary suppression protocol among Bologna poor responders undergoing ovarian stimulation using corifollitropin alfa: does it play any role?

Author

Errázuriz, Joaquin, Drakopoulos, Panagiotis, Pening, David, Racca, Annalisa, Romito, Alessia, De Munck, Nelke, Tournaye, Herman, De Vos, M, Blockeel, Christophe, Errázuriz, Joaquin, Drakopoulos, Panagiotis, Pening, David, Racca, Annalisa, Romito, Alessia, De Munck, Nelke, Tournaye, Herman, De Vos, M, and Blockeel, Christophe

Abstract

Research question: Does the type of pituitary suppression protocol influence cumulative live birth rate (LBR) in Bologna poor responders treated with corifollitropin alfa (CFA)? Design: Retrospective cohort analysis including poor responder patients fulfilling the Bologna criteria who underwent their first intracytoplasmic sperm injection cycle using a CFA-based ovarian stimulation protocol between 2011 and 2017. The starting dose of CFA was 150 µg. The primary outcome was cumulative LBR, defined as the first delivery of a live born resulting from the fresh and all the subsequent frozen embryo transfers. Results: A total of 717 cycles were divided into three groups: A (gonadotrophin-releasing hormone [GnRH] antagonist protocol, n = 407), B (long GnRH agonist protocol, n = 224) and C (short GnRH agonist protocol, n = 86). Cumulative LBR did not significantly differ between groups (20.1% versus 17.4% versus 14.0%; P = 0.35). Significantly more patients in Group A had supernumerary embryos cryopreserved (28.3% versus 18.4% versus 11.6%; P < 0.001). Days of additional highly purified human menopausal gonadotrophin 300 IU injections following CFA were significantly different between Groups A, B and C (3 versus 5 versus 3 days; P < 0.001). Multivariate logistic regression analysis showed that the number of oocytes retrieved remained an independent predictive factor (odds ratio 1.23, 95% confidence interval 1.16–1.31) for cumulative LBR. Conclusions: Poor responders according to the Bologna criteria in whom CFA is used for ovarian stimulation had comparable cumulative LBR, irrespective of the type of pituitary suppression. An increase in number of oocytes retrieved is an independent variable related to cumulative LBR., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

26. Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience

Author

Marchetti, Claudia, primary, Musella, Angela, additional, Romito, Alessia, additional, Vertechy, Laura, additional, Palaia, Innocenza, additional, Di Donato, Violante, additional, Boccia, Serena, additional, De Felice, Francesca, additional, Monti, Marco, additional, Muzii, Ludovico, additional, and Benedetti Panici, Pierluigi, additional

Published
2017
Full Text
View/download PDF

27. Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions

Author

Musella, Angela, primary, Vertechy, Laura, additional, Romito, Alessia, additional, Marchetti, Claudia, additional, Giannini, Andrea, additional, Sciuga, Valentina, additional, Bracchi, Carlotta, additional, Tomao, Federica, additional, Di Donato, Violante, additional, De Felice, Francesca, additional, Monti, Marco, additional, Muzii, Ludovico, additional, and Benedetti Panici, Pierluigi, additional

Published
2016
Full Text
View/download PDF

28. Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions.

Author

Musella, angela, Vertechy, Laura, Romito, alessia, Marchetti, Claudia, Giannini, andrea, Sciuga, Valentina, Bracchi, Carlotta, Tomao, Federica, Di Donato, Violante, De Felice, Francesca, Monti, Marco, Muzii, Ludovico, and Benedetti Panici, Pierluigi

Subjects
OVARIAN cancer treatment, BEVACIZUMAB, CYTOREDUCTIVE surgery, DRUG dosage, CANCER relapse, ADJUVANT treatment of cancer, CANCER invasiveness
Abstract

Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinum-based chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors. Despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, and timing of bevacizumab still exists. This review summarizes the state of the art on the use of bevacizumab for ovarian cancer in front-line, recurrence, and neoadjuvant settings. This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results